Selectis Health (GBCS) AI Stock Analysis

• Market Cap: $6.44M
• Dividend Yield: N/A
• Average Volume (3M): 9.63K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.62
• Revenue Growth: 10.76%
• EPS Growth: 48.67%
• Country: US
• Employees: 616
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.80
• Shares Outstanding: 3,067,059
• 10 Day Avg. Volume: 3,797
• 30 Day Avg. Volume: 9,627
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 5.81
• Enterprise Value/Revenue: 0.95
• Enterprise Value/Gross Profit: 4.30
• Enterprise Value/Ebitda: -29.18
• 1Y Price Target: $2.00
• Price Target Upside: -9.09% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: $2.00 ▼(-9.09% Downside)

Selectis Health's overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and negative equity. Technical indicators show a lack of momentum, and valuation metrics reflect ongoing financial difficulties. The absence of earnings call data and corporate events means these factors do not influence the score.

Selectis Health Business Overview & Revenue Model

Company Description

Global Healthcare REIT, Inc. (the "Company" or "Global") was organized with the intent of operating as a real estate investment trust (REIT) for the purpose of investing in real estate and other assets related to the healthcare industry. The Company's focus has partially shifted from leasing nursing home assets to independent operators toward owning and operating its real estate assets itself. As a result, the Company no longer intends to elect to qualify as a REIT and is currently considering changing its name and other charter provisions to better reflect its current business model. Prior to the Company changing its name to Global Healthcare REIT, Inc. on September 30, 2013, the Company was known as Global Casinos, Inc. Global Casinos, Inc. operated two gaming casinos which were split-off and sold on September 30, 2013. Simultaneous with the split-off and sale of the gaming operations, the Company acquired West Paces Ferry Healthcare REIT, Inc. (WPF) in a transaction accounted for as a reverse acquisition whereby WPF was deemed to be the accounting acquirer. The Company acquires, develops, leases, manages and disposes of healthcare real estate, and provides financing to healthcare providers. As of September 30, 2020, the Company owned twelve healthcare properties which are either leased or managed by third-party operators under triple-net operating terms or operated directly by the Company. The Company operates the facilities internally when advantageous and expedient.

How the Company Makes Money

Selectis Health generates revenue through multiple streams, primarily by selling its software products and services to healthcare providers and organizations. Key revenue streams include licensing fees for its electronic health record systems, subscription fees for its telehealth platforms, and consulting services that help healthcare institutions implement and optimize these technologies. Additionally, the company may form strategic partnerships with healthcare entities and technology providers, enhancing its market reach and creating additional revenue opportunities through joint ventures or collaborative projects. These partnerships can lead to bundled service offerings or shared revenue models that further contribute to the company's financial performance.

Selectis Health Financial Statement Overview

Summary

Selectis Health faces significant financial challenges with consistent net losses, high leverage, and negative equity. Despite some revenue growth, profitability and liquidity issues persist, requiring strategic restructuring to enhance financial health.

Income Statement

Selectis Health shows fluctuating revenue growth with a significant increase in 2024. However, the company continues to experience negative net income and EBIT, indicating ongoing profitability challenges. The negative EBIT and EBITDA margins over the years highlight operational inefficiencies.

Balance Sheet

The company's financial stability is weak, characterized by high levels of debt and negative stockholders' equity in 2024, suggesting insolvency risk. The negative ROE reflects the inability to generate profits from shareholders' investments, and the equity ratio is negative, further indicating financial distress.

Cash Flow

While Selectis Health has experienced some growth in free cash flow in 2024, it remains negative, limiting financial flexibility. The negative operating cash flow to net income ratio further underscores cash management issues, posing liquidity challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	39.49M	36.78M	40.60M	29.29M	20.93M
Gross Profit	9.13M	5.41M	10.74M	7.81M	7.54M
EBITDA	1.19M	-7.29M	1.51M	1.00M	4.96M
Net Income	-2.42M	-3.97M	-2.40M	-2.25M	2.96M
Balance Sheet
Total Assets	33.45M	40.67M	42.49M	46.92M	45.93M
Cash, Cash Equivalents and Short-Term Investments	680.33K	1.48M	1.42M	3.96M	3.59M
Total Debt	32.23M	37.25M	37.89M	38.50M	39.50M
Total Liabilities	38.86M	43.64M	41.54M	43.82M	42.72M
Stockholders Equity	-5.41M	-2.96M	952.84K	3.10M	3.41M
Cash Flow
Free Cash Flow	-1.86M	506.86K	-527.51K	-790.50K	1.75M
Operating Cash Flow	-1.82M	536.67K	-305.15K	-270.93K	2.73M
Investing Cash Flow	2.45M	-29.80K	-222.36K	-519.58K	-1.57M
Financing Cash Flow	-1.54M	-618.74K	-1.85M	1.61M	1.82M

Selectis Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GBCS, the sentiment is Negative. The current price of 2.2 is above the 20-day moving average (MA) of 2.17, below the 50-day MA of 2.30, and above the 200-day MA of 2.05, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GBCS.

Selectis Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	57 Neutral	$18.88M	-7.85	-9.97%	―	26.61%	-156.30%
CCEL	50 Neutral	$38.67M	-205.13	1.10%	8.33%	1.10%	98.13%
CCM	46 Neutral	$27.03M	-0.63	13.52%	―	-29.82%	-2.57%
SYRA	44 Neutral	$835.74K	-0.45	-130.59%	―	14.07%	76.85%
GBCS	40 Underperform	$6.44M	―	113.38%	―	10.76%	48.67%
MODVQ	40 Underperform	$2.56M	-0.01	523.15%	―	-0.70%	-2.38%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Selectis Health Corporate Events

Selectis Health Stock Approved for OTCQB Upgrade

On June 20, 2025, Selectis Health was informed by the OTC Markets Group, Inc. that its common stock received approval for upgraded quotation on the OTCQB. Trading under the ticker symbol ‘GBCS’ is set to commence on June 23, 2025, marking a significant step in enhancing the company’s market visibility and accessibility.